1 / 38

PCI for patients with Chronic Renal Dysfunction

PCI for patients with Chronic Renal Dysfunction. Dr. Liyi First Affiliated Hospital of Sun Yat-sen University. With the aging of society and development of PCI techniques, we are facing more and more CAD patients with CRD

cecilia-anthony
Télécharger la présentation

PCI for patients with Chronic Renal Dysfunction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PCI for patients with Chronic Renal Dysfunction Dr. Liyi First Affiliated Hospital of Sun Yat-sen University

  2. With the aging of society and development of PCI techniques, we are facing more and more CAD patients with CRD • Our hospital has a very large hemodialysis and peritoneal dialysis center, we are facing more and more CRD patients • Serum creatine level is a very poor indicator for patient’s renal function • Depleted renal function means poor prognosis

  3. Freedom from Cardiac Death for Patients with CKD* and Diabetes (DM) BARI Trial + Registry 95% 85% 77% 54% With DM or CKD (n=2921) With DM, without CKD (n=611) Without DM, with CKD (n=46) With both DM and CKD (n=30) * CKD defined as baseline Cr > 1.5 mg/dl Szczech L. et al., Circulation 2002; 105:2253-8.

  4. 100% 80% 60% 40% 20% 0% 0 1 2 3 4 5 6 7 8 9 10 11 12 CIN After PCI: Cr. Increase & DM 1-Year Event-Free Survival 80% 80% 64% 55% Event-Free Survival DM, <25% creatinine increase No DM, <25% creatinine increase DM, 25% creatinine increase No DM, 25% creatinine increase Time (Months) Gruberg, et al. JACC 2000; 36: 1542-8

  5. The best strategies is to nip CIN in the bud • So… who are at the high risk ?

  6. Risk Factors for CIN

  7. Risk of CIN Relation to Baseline Creatinine 30 20 10 0 Probability of Nephrotoxicity (%) 0.5 1.0 1.5 2.0 Baseline Serum Creatinine(mg/dl) Davidson et al. Annals Int Med (1989)

  8. 100 90 80 70 60 50 40 30 20 10 0 Prediction of CIN and Dialysis After PCI Mean age=65 years, 72 kg man CIN CrCl ~ 30 mL/min 30–40% CIN rate n=424 n=3695 n=7586 Dialysis Renal Event Rate (%) No diabetics Diabetics 50 40 30 20 10 Calculated CrCl (mL/min) Independent risk factors: CrCl>>Diabetes>>Contrast Volume PCI, percutaneous coronary intervention. Data adapted from: Berns AS. Kidney Int. 1989;36(4):730–740; McCullough PA. Am J Med. 1997;103:386–375;Rihal et al. Circulation. 2002;105:2259–2264.

  9. Predictors of ARF +Dialysis OR CI P Cr Clearance 0.83 0.77-0.89 <0.001 Diabetes 5.47 1.41-21.32 0.01 Contrast dose 1.008 1.002-1.013 0.01 CIN: Incidence & Risk Factors • 1,826 consecutive pts undergoing PCI:CIN without dialysis occurred 14.5%CIN with dialysis occurred 0.8% McCullough, et al. Am J Med 1997; 103: 375

  10. Be aware of small body weight old ladies eg. Female, Scr = 80 umol/L , age =60, wt = 60kg  CCr = 62.4 ml/min • if. Female, Scr = 80 umol/L , age = 80 , wt = 45kg  CCr = 35.1 ml/min

  11. A Risk Score for Prediction of CIN Multivariate Predictors Diabetes – any Tx Age over 70 SVG treated Multiple vessels treated Female IABP use Acute coronary syndrome CrCl <50 mL/min 60 P<.0001 χ2 by trend 50 40 30 20 10 0 0 or 1 2 3 4 5 6 7 or 8 CIN Risk Score Mehran R et al. J Am Coll Cardiol. 2003;41:37A.

  12. Scheme to define CIN risk score Risk Factors Integer Score Hypotension 5 IABP 5 CHF 5 Age >75 years 4 Anemia 3 Diabetes 3 Calculate Contrast media volume 1 for each 100 cc3 Serum creatine > 1.5mg/dl 4 OR 2 for 40 – 60 4 for 20 – 40 6 for < 20 eGFR <60ml/min/1.73 m2 eGFR < 60ml/min/1.73 m2 = 186 x (SCr)-1.154 x (Age)-0.203 X (0.742 if female) x (1.210 if African American) Mehran et al. JACC 2004;44:1393-1399.

  13. How to prevent … • Minimize Contrast dosage • Hydration • N-AC • Type of Contrast Media ?

  14. Minimize Contrast Dosage My Tips • Staged procedure • Use your syringe wisely • Plan twice, inject once • Diluted contrast for visualization vessels • Use roadmap wisely • Use your flat panel DSA wisely

  15. Hydration

  16. Prevention of CIN: Hydration • 78 Pts with CRI (Cr 1.6-4.2 mg/dl) • IV Fluids: 1/2 NS @ 1ml/kg/hr for 12 hr before & after contrast • Mannitol: 50 g 1 hr before contrast • Furosemide: 80 mg IV 30 min before contrast 60% 43% Non-DM DM 50% 38% 40% 36% % CIN 30% 20% 17% 14% 7% 10% 0% Saline Saline + Mannitol Saline + Furosemide Solomon, et al. NEJM 1994; 331: 1416-1420

  17. Sodium Bicarbonate Shea E. Hogan et al. AHJ 2008;156:414

  18. Question remaining in hydration • When ? • What ? • How many ? • How ?

  19. N-ACETYLCYSTEINE (NAC) ?

  20. Meta-analysis: NAC Randomized,13 Controlled Trials : N=1882 Zagler A, et al. AHJ 2006;151:140

  21. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy Kelly, A. M. et. al. Ann Intern Med 2008;148:284-294

  22. Contrast Agent – remaining questions Iso-osmolarity vs. Low osmolarity

  23. My protocol in dealing high risk patients • Identify high risk patients • Take preventive measures • Check Scr before and after procedure

  24. Patients Characteristics • Male, 65yrs • Exertional angina for 1 weeks • History: DM (on oral medication) dyslipidemia, Hypertension • Lab. Exam: LDL: 3.1 mmol/L TNT: 1.1 ng/ml SCr: 135 umol/L

  25. Risk Assessment CCr: 44 ml/min Diabetes – any Tx Acute coronary syndrome CrCl <50 mL/min

  26. Preventive measures • Hydration • N-AC • Change oral hypoglycemic into insuline • Patients and family consent • Baseline SCr: 135umol/L

  27. 下一步的治疗策略： 1，LCX； 2，LAD； 3，RCA。

  28. Follow-up D2 Scr: 128 umol/L D3 Scr: 130 umol/L

  29. 谢谢！

More Related